S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7)
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843736.56298.a7 |
| _version_ | 1797287212990070784 |
|---|---|
| author | A. Sureda J. Westin F. L. Locke M. Dickinson A. Ghobadi M. Elsawy T. van Meerten D. B. Miklos M. Ulrickson M.-A. Perales U. Farooq L. Wannesson L. Leslie M. J. Kersten C. A. Jacobson J. M. Pagel G. Wulf P. Johnston A. P. Rapoport L. I. Gordon Y. Yang A. Peng L. Du J. T. Snider J. Shah M. Schupp P. Cheng C. To O. O. Oluwole |
| author_facet | A. Sureda J. Westin F. L. Locke M. Dickinson A. Ghobadi M. Elsawy T. van Meerten D. B. Miklos M. Ulrickson M.-A. Perales U. Farooq L. Wannesson L. Leslie M. J. Kersten C. A. Jacobson J. M. Pagel G. Wulf P. Johnston A. P. Rapoport L. I. Gordon Y. Yang A. Peng L. Du J. T. Snider J. Shah M. Schupp P. Cheng C. To O. O. Oluwole |
| author_sort | A. Sureda |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:29:41Z |
| format | Article |
| id | doaj.art-21f534b45c9e4611aeebe693787af305 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:29:41Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-21f534b45c9e4611aeebe693787af3052024-03-02T06:40:43ZengWileyHemaSphere2572-92412022-06-01611211310.1097/01.HS9.0000843736.56298.a7202206003-00112S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7)A. Sureda0J. Westin1F. L. Locke2M. Dickinson3A. Ghobadi4M. Elsawy5T. van Meerten6D. B. Miklos7M. Ulrickson8M.-A. Perales9U. Farooq10L. Wannesson11L. Leslie12M. J. Kersten13C. A. Jacobson14J. M. Pagel15G. Wulf16P. Johnston17A. P. Rapoport18L. I. Gordon19Y. Yang20A. Peng21L. Du22J. T. Snider23J. Shah24M. Schupp25P. Cheng26C. To27O. O. Oluwole281 Hematology Department, Institut Català d’Oncologia-Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain2 The University of Texas MD Anderson Cancer Center, Houston3 Moffitt Cancer Center, Tampa, United States of America4 Peter MacCallum Cancer Centre, Royal Melbourne Hospital and the University of Melbourne, Melbourne, Victoria, Australia5 Washington University School of Medicine, St Louis, United States of America6 Division of Hematology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada7 University Medical Center Groningen, on behalf of HOVON/LLPC, Groningen, Netherlands8 Stanford University School of Medicine, Stanford9 Banner MD Anderson Cancer Center, Gilbert10 Memorial Sloan-Kettering Cancer Center, New York11 University of Iowa, Iowa City, United States of America12 Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland13 John Theurer Cancer Center, Hackensack, United States of America14 Amsterdam UMC, University of Amsterdam, on behalf of HOVON/LLPC, Amsterdam, Netherlands15 Dana-Farber Cancer Institute, Boston16 Swedish Cancer Institute, Seattle, United States of America17 University Medicine Göttingen, Göttingen, Germany18 Mayo Clinic, Rochester19 University of Maryland School of Medicine and Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore20 Northwestern University Feinberg School of Medicine, Chicago21 Kite, a Gilead Company, Santa Monica21 Kite, a Gilead Company, Santa Monica21 Kite, a Gilead Company, Santa Monica21 Kite, a Gilead Company, Santa Monica21 Kite, a Gilead Company, Santa Monica21 Kite, a Gilead Company, Santa Monica21 Kite, a Gilead Company, Santa Monica21 Kite, a Gilead Company, Santa Monica22 Vanderbilt University Cancer Center, Nashville, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000843736.56298.a7 |
| spellingShingle | A. Sureda J. Westin F. L. Locke M. Dickinson A. Ghobadi M. Elsawy T. van Meerten D. B. Miklos M. Ulrickson M.-A. Perales U. Farooq L. Wannesson L. Leslie M. J. Kersten C. A. Jacobson J. M. Pagel G. Wulf P. Johnston A. P. Rapoport L. I. Gordon Y. Yang A. Peng L. Du J. T. Snider J. Shah M. Schupp P. Cheng C. To O. O. Oluwole S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7) HemaSphere |
| title | S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7) |
| title_full | S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7) |
| title_fullStr | S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7) |
| title_full_unstemmed | S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7) |
| title_short | S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7) |
| title_sort | s211 clinical and patient reported outcomes in a phase 3 study of axicabtagene ciloleucel axi cel vs standard of care in elderly patients with relapsed refractory large b cell lymphoma zuma 7 |
| url | http://journals.lww.com/10.1097/01.HS9.0000843736.56298.a7 |
| work_keys_str_mv | AT asureda s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT jwestin s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT fllocke s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT mdickinson s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT aghobadi s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT melsawy s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT tvanmeerten s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT dbmiklos s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT mulrickson s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT maperales s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT ufarooq s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT lwannesson s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT lleslie s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT mjkersten s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT cajacobson s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT jmpagel s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT gwulf s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT pjohnston s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT aprapoport s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT ligordon s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT yyang s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT apeng s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT ldu s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT jtsnider s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT jshah s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT mschupp s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT pcheng s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT cto s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 AT oooluwole s211clinicalandpatientreportedoutcomesinaphase3studyofaxicabtageneciloleucelaxicelvsstandardofcareinelderlypatientswithrelapsedrefractorylargebcelllymphomazuma7 |